Dicerna Pharmaceuticals, Inc., A Novo Nordisk Company
Clinical trials sponsored by Dicerna Pharmaceuticals, Inc., A Novo Nordisk Company, explained in plain language.
-
New hope for rare kidney disease: drug targets oxalate buildup in severe cases
Disease control Recruiting nowThis phase 2 study tests a drug called nedosiran (DCR-PHXC) in 28 people with primary hyperoxaluria type 1 (PH1) who have severe kidney impairment, with or without dialysis. The goal is to see if the drug safely lowers plasma oxalate levels, which can cause kidney stones and dama…
Phase: PHASE2 • Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New cancer drug candidate enters first human safety trial
Disease control Recruiting nowThis early-stage study is testing a new drug called DCR-PDL1 in about 32 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and how the body processes it, not to cure the cancer. Participants will receive …
Phase: PHASE1 • Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC